Table 2.

Treatment-Related Toxicity

Event	Doses Below the MTD (all schedules pooled; n = 21)		Schedule 1* MTD (1.88 mg/kg; n = 43)		Schedule 2† MTD (1.5 mg/kg; n = 6)		Schedule 3‡ MTD (1.0 mg/kg; n = 15)		Doses Above the MTD (all schedules pooled; n = 32)
	All Grades	Grade 3 or Higher	All Grades	Grade 3 or Higher	All Grades	Grade 3 or Higher	All Grades	Grade 3 or Higher	All Grades	Grade 3 or Higher
Nonhematologic toxicity
Rash	14	—	74	30	67	—	67	33	81	22
Fatigue	14	—	65	7	67	17	53	13	63	13
Pruritus	10	—	63	—	33	—	47	7	59	3
Alopecia	—	—	65	—	33	—	33	—	41	—
Diarrhea	10	—	47	2	67	—	20	—	38	6
Neuropathy	5	—	33	7	33	17	60	27	34	3
Nausea	5	—	35	—	50	—	7	—	41	—
Anorexia	—	—	40	—	33	—	13	—	28	3
Dysgeusia	—	—	33	—	33	—	13	—	16	—
Constipation	—	—	30	—	17	—	20	—	16	—
Vomiting	5	—	14	—	17	—	13	—	25	—
Myalgia	—	—	12	—	—	—	27	13	19	6
Dry skin	—	—	12	—	33	—	13	—	9	—
Pyrexia	—	—	19	—	—	—	—	—	13	—
Pain in extremity	—	—	14	5	17	—	13	—	6	—
Arthralgia	—	—	7	—	17	—	7	7	16	6
Mucosal inflammation	—	—	14	—	—	—	7	—	9	6
Palmar-plantar erythrodysesthesia syndrome	—	—	5	—	—	—	7	—	13	6
Hyperglycemia	—	—	—	—	—	—	—	—	6	6
Hematologic toxicity
Neutropenia	5	5	28	19	33	17	13	13	22	19
Thrombocytopenia	—	—	5	2	—	—	—	—	6	3
Leukopenia	5	5	2	2	—	—	—	—	—	—

NOTE. Data are shown as the percentage of patients experiencing the event. Listed are events that occurred at any severity in > 10% of patients or at grade 3 or higher severity in ≥ 2% of patients.

Abbreviations: MTD, maximum-tolerated dose.

^*Schedule 1: once every 3 weeks.

^†Schedule 2: once per week for 2 of 3 weeks.

^‡Schedule 3: once per week.